{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Combination+pill&page=7", "query": { "intervention": "Combination pill", "page": 7 }, "page_size": 10 }, "pagination": { "page": 7, "page_size": 10, "total_count": 341, "total_pages": 35, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Combination+pill&page=8&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Combination+pill&page=6&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-03T07:19:32.412Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT06263231", "title": "A Study to Investigate Efficacy & Safety of Intratumoral INT230-6 Compared to US Standard of Care in Adults With Soft Tissue Sarcomas (INVINCIBLE-3)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Sarcoma,Soft Tissue" ], "interventions": [ { "name": "INT230-6", "type": "DRUG" }, { "name": "Eribulin", "type": "DRUG" }, { "name": "Trabectedin", "type": "DRUG" }, { "name": "Pazopanib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Intensity Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 333, "start_date": "2024-06-28", "completion_date": "2028-12", "has_results": false, "last_update_posted_date": "2026-08-11", "last_synced_at": "2026-11-03T07:19:32.412Z", "location_count": 10, "location_summary": "Los Angeles, California • Santa Monica, California • New Haven, Connecticut + 5 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Farmington Hills", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT06263231" }, { "nct_id": "NCT00504816", "title": "A Study of the Effects of GSK189075 on PK Profiles of an Oral Contraceptive Pill When Given to Healthy Female Volunteers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Type 2 Diabetes Mellitus", "Diabetes Mellitus, Type 2" ], "interventions": [ { "name": "GSK189075", "type": "DRUG" }, { "name": "Brevicon", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "45 Years", "sex": "FEMALE", "summary": "18 Years to 45 Years · Female only" }, "enrollment_count": 22, "start_date": "2007-04", "completion_date": "2008-04", "has_results": false, "last_update_posted_date": "2012-06-04", "last_synced_at": "2026-11-03T07:19:32.412Z", "location_count": 1, "location_summary": "Miramar, Florida", "locations": [ { "city": "Miramar", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00504816" }, { "nct_id": "NCT00451204", "title": "A Combination Trial of Copaxone Plus Estriol in Relapsing Remitting Multiple Sclerosis (RRMS)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Relapsing Remitting Multiple Sclerosis" ], "interventions": [ { "name": "Estriol", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Copaxone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of California, Los Angeles", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "50 Years", "sex": "FEMALE", "summary": "18 Years to 50 Years · Female only" }, "enrollment_count": 158, "start_date": "2007-03", "completion_date": "2014-07", "has_results": true, "last_update_posted_date": "2016-06-16", "last_synced_at": "2026-11-03T07:19:32.412Z", "location_count": 15, "location_summary": "Scottsdale, Arizona • Los Angeles, California • Aurora, Colorado + 12 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Kansas City", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00451204" }, { "nct_id": "NCT04723147", "title": "DTA (Dopaminergic Therapy for Anhedonia) Study", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Depression", "Anhedonia" ], "interventions": [ { "name": "Carbidopa Levodopa", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Emory University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "25 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "25 Years to 55 Years" }, "enrollment_count": 19, "start_date": "2021-01-29", "completion_date": "2023-10-11", "has_results": true, "last_update_posted_date": "2024-12-16", "last_synced_at": "2026-11-03T07:19:32.412Z", "location_count": 1, "location_summary": "Atlanta, Georgia", "locations": [ { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT04723147" }, { "nct_id": "NCT04518306", "title": "Efficacy and Safety of GMRx2 Compared to Placebo for the Treatment of Hypertension", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Hypertension" ], "interventions": [ { "name": "Telmisartan 10 mg/amlodipine 1.25 mg/indapamide 0.625 mg", "type": "DRUG" }, { "name": "Telmisartan 20 mg/amlodipine 2.5 mg/indapamide 1.25 mg", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "George Medicines PTY Limited", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 755, "start_date": "2021-06-14", "completion_date": "2023-10-18", "has_results": true, "last_update_posted_date": "2025-06-03", "last_synced_at": "2026-11-03T07:19:32.412Z", "location_count": 23, "location_summary": "Phoenix, Arizona • Scottsdale, Arizona • Tucson, Arizona + 17 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "South Gate", "state": "California" }, { "city": "Tarzana", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04518306" }, { "nct_id": "NCT06272370", "title": "Individualizing Treatment for Asthma in Primary Care", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Asthma", "Bronchial Diseases", "Respiratory Tract Infections", "Lung Diseases, Obstructive", "Lung Diseases", "Respiratory Hypersensitivity", "Immune System Diseases" ], "interventions": [ { "name": "Asthma Symptom Monitoring online tools", "type": "OTHER" }, { "name": "Inhaled Steroids", "type": "DRUG" }, { "name": "Azithromycin Pill", "type": "DRUG" } ], "intervention_types": [ "OTHER", "DRUG" ], "sponsor": "DARTNet Institute", "sponsor_class": "OTHER_GOV", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "12 Years to 75 Years" }, "enrollment_count": 103, "start_date": "2024-02-01", "completion_date": "2024-12-31", "has_results": true, "last_update_posted_date": "2025-04-20", "last_synced_at": "2026-11-03T07:19:32.412Z", "location_count": 1, "location_summary": "Aurora, Colorado", "locations": [ { "city": "Aurora", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT06272370" }, { "nct_id": "NCT04645602", "title": "Merck IIT: RRP Pembro and Lenvatinib", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Human Papilloma Virus", "Recurrent Respiratory Papillomatosis", "Pulmonary Disease" ], "interventions": [ { "name": "Lenvatinib", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Yale University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 20, "start_date": "2025-07-18", "completion_date": "2027-12", "has_results": false, "last_update_posted_date": "2026-07-02", "last_synced_at": "2026-11-03T07:19:32.412Z", "location_count": 1, "location_summary": "New Haven, Connecticut", "locations": [ { "city": "New Haven", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT04645602" }, { "nct_id": "NCT01205685", "title": "Endocrine Therapy + OSI-906 With or Without Erlotinib for Hormone-Sensitive Metastatic Breast Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hormone-sensitive Metastatic Breast Cancer" ], "interventions": [ { "name": "OSI-906", "type": "DRUG" }, { "name": "Erlotinib", "type": "DRUG" }, { "name": "Letrozole", "type": "DRUG" }, { "name": "Goserelin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Vanderbilt-Ingram Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 11, "start_date": "2010-05", "completion_date": "2011-07", "has_results": true, "last_update_posted_date": "2012-09-11", "last_synced_at": "2026-11-03T07:19:32.412Z", "location_count": 3, "location_summary": "Franklin, Tennessee • Nashville, Tennessee", "locations": [ { "city": "Franklin", "state": "Tennessee" }, { "city": "Nashville", "state": "Tennessee" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT01205685" }, { "nct_id": "NCT04666649", "title": "Pegcrisantaspase in Combination With Venetoclax for Treatment of Relapsed or Refractory Acute Myeloid Leukemia (R/R AML)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Relapsed or Refractory Acute Myeloid Leukemia" ], "interventions": [ { "name": "Venetoclax and pegcrisantaspase", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Maryland, Baltimore", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 27, "start_date": "2021-03-10", "completion_date": "2025-05-23", "has_results": false, "last_update_posted_date": "2025-10-07", "last_synced_at": "2026-11-03T07:19:32.412Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT04666649" }, { "nct_id": "NCT02401737", "title": "Dose-Ranging Study to Assess the Safety, PK and Initial Antiviral Efficacy of NVR 3-778 in Chronic HBV Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Chronic Hepatitis B" ], "interventions": [ { "name": "NVR 3-778", "type": "DRUG" }, { "name": "Placebo for NVR 3-778", "type": "DRUG" }, { "name": "Pegasys", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novira Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 58, "start_date": "2015-01-31", "completion_date": "2016-05-18", "has_results": false, "last_update_posted_date": "2017-10-18", "last_synced_at": "2026-11-03T07:19:32.412Z", "location_count": 4, "location_summary": "Costa Mesa, California • Pasadena, California • San Diego, California + 1 more", "locations": [ { "city": "Costa Mesa", "state": "California" }, { "city": "Pasadena", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02401737" } ] }